{
    "2018-10-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "4 Reasons to Be Wary of This Animal Health IPO",
                "features": {
                    "keywords": [
                        "IPO",
                        "animal health",
                        "wary"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes",
                "features": {
                    "keywords": [
                        "Lilly",
                        "GIP",
                        "GLP-1",
                        "HbA1c",
                        "body weight",
                        "Type 2 Diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diabetes"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "A Look at Novartis’s Valuation on October 9",
                "features": {
                    "keywords": [
                        "Novartis",
                        "valuation"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-09",
                "original_text": "Assessing Novartis’s Performance in October So Far",
                "features": {
                    "keywords": [
                        "Novartis",
                        "performance",
                        "October"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "5 Companies Hit 52-Week Highs",
                "features": {
                    "keywords": [
                        "companies",
                        "52-week highs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "A Walk-Through of Eli Lilly’s Alzheimer’s Disease Portfolio",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Alzheimer’s",
                        "disease",
                        "portfolio"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "neurology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}